Hypothesis

If the ordered sequestration of mitochondria, ER, lysosomes, and finally nucleus during autophagy is perturbed—specifically by delaying mitophagy while accelerating nucleophagy—then plasma cfDNA will show a premature increase in long (>150 bp) fragments bearing hypomethylated LINE/Alu signatures, independent of overall autophagy flux.

Mechanistic rationale

Autophagy degrades substrates in a defined hierarchy: mitochondria first (mitophagy), then ER fragments (reticulophagy), lysosomes (lysophagy), and ultimately nuclear material (nucleophagy) when stress persists. This sequence ensures that organelles that generate reactive oxygen species are cleared before the nucleus is exposed to autophagic machinery, limiting the release of heavily methylated, nucleosome‑protected DNA. When mitophagy is impaired, damaged mitochondria accumulate, releasing mtDNA that triggers cGAS‑STING signaling and promotes a senescence‑associated secretory phenotype (SASP). Senescent cells exhibit chromatin relaxation and increased lysosomal permeability, which accelerates nucleophagy and leads to the expulsion of large, hypomethylated nuclear fragments. Consequently, the plasma cfDNA pool becomes enriched for long fragments that retain the hypomethylated state of repetitive elements, amplifying TLR9‑driven inflammation.

Testable predictions

1. Chronology of fragment appearance – In a mitophagy‑deficient mouse model (e.g., Pink1‑/‑), long cfDNA fragments (>150 bp) will rise earlier than in wild‑type littermates, despite comparable LC3‑II levels indicating unchanged bulk autophagy flux.
2. Methylation signature – The early‑appearing long fragments will show greater hypomethylation at LINE‑1 and Alu CpGs compared with short fragments isolated from the same plasma fraction.
3. Nucleophagy dependence – Genetic or pharmacological inhibition of nucleophagy (e.g., ATG‑dependent histone H2B knock‑down or use of the nucleophagy inhibitor Spautin‑1 at low dose) will blunt the increase in long cfDNA fragments in Pink1‑/‑ mice without rescuing mitochondrial defects.
4. Inflammatory read‑out – Plasma from Pink1‑/‑ mice will exhibit elevated TNF‑α and IL‑6 levels that correlate with the proportion of hypomethylated long cfDNA fragments; neutralizing TLR9 will decouple cfDNA length from cytokine production.

Experimental design (outline)

• Animals: Wild‑type, Pink1‑/‑, and Pink1‑/‑;Atg7^fl/fl;Vav‑Cre (hematopoietic‑specific autophagy rescue) mice, aged 3, 6, and 12 months.
• Plasma collection: Cardiac puncture under anesthesia, cfDNA isolated via silica‑column kit, fragment size analyzed by Bioanalyzer, methylation assessed by bisulfite‑sequencing of LINE‑1/Alu amplicons.
• Interventions: Chronic low‑dose Spautin‑1 (10 mg/kg i.p., 3×/week) to attenuate nucleophagy; control receives vehicle.
• Read‑outs: cfDNA fragment distribution, LINE‑1/Alu methylation %, plasma cytokines (ELISA), tissue markers of mitophagy (mt‑Keima), nucleophagy (LC3‑colocalization with histone H3).

Falsifiability

If long cfDNA fragments and their hypomethylation do not increase in Pink1‑/‑ mice despite confirmed mitophagy blockade, or if nucleophagy inhibition fails to normalize the long‑fragment pool, the hypothesis would be refuted. Likewise, if blocking TLR9 abolishes inflammation without altering cfDNA length, the proposed causal link between fragment characteristics and innate signaling would be unsupported.

Broader implication

This model positions autophagy’s substrate hierarchy as a quality‑control checkpoint that shapes the immunogenic landscape of circulating DNA. Therapeutic strategies aimed at restoring the proper order—enhancing mitophagy while restraining premature nucleophagy—could mitigate inflammaging by preserving a cfDNA profile dominated short, methylated fragments that are less prone to activate TLR9.